CLSA "sell" report on Biocon is illogical n reflects poor understanding of huge opp for Biosimilars Axis has a "Buy" on Biocon on same .
— Kiran Mazumdar Shaw (@kiranshaw) January 6, 2016
@ashurathi and I don't like analysts like you who report without bothering to understand our business model
— Kiran Mazumdar Shaw (@kiranshaw) January 6, 2016
@kiranshaw quite obvious that according to you only those analysts who are talking +ve on ur co. understand the business model. Right?
— Ashish Rathi (@ashurathi) January 6, 2016
@ashurathi yes u got it!
— Kiran Mazumdar Shaw (@kiranshaw) January 6, 2016